MedTrace Logo

The Trial of SHR6508 in Secondary Hyperparathyroidism

NCT06434961 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 498

Last updated 2025-12-12

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

Conditions

  • Secondary Hyperparathyroidism

Interventions

DRUG

SHR6508 plus oral placebo tablets

SHR6508 plus oral placebo tablets

DRUG

Cinacalcet plus intravenous placebo

Cinacalcet plus intravenous placebo

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2025-09-29
Completion
2025-11-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06434961 on ClinicalTrials.gov